Arrowhead Pharmaceuticals (ARWR) Change in Acquisitions & Divestments (2011 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 15 years of Change in Acquisitions & Divestments data on file, last reported at $9.2 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 96.0% year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $466.7 million (down 19.68% YoY) and the FY2025 annual result came in at $689.6 million, up 55.9% from the prior year.
• Change in Acquisitions & Divestments retreated to $9.2 million in Q1 2026, from $115.3 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $240.5 million in Q2 2025 to a low of $9.2 million in Q1 2026.
• A 5-year average of $106.8 million and a median of $101.8 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments jumped 314.42% — and 2026, when it plunged 96.0%.
• Tracing ARWR's Change in Acquisitions & Divestments over 5 years: stood at $69.4 million in 2022, then jumped by 92.31% to $133.5 million in 2023, then slipped by 11.48% to $118.2 million in 2024, then retreated by 2.4% to $115.3 million in 2025, then sank by 92.04% to $9.2 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $9.2 million (Q1 2026), $115.3 million (Q4 2025), and $101.8 million (Q3 2025), per Business Quant data.